Old Drugs, New Cures Act

General issues related to health care and pharmaceuticals; drug pricing; patent reform; Medicare issues, including drug price negotiations; FDA issues; FTC issues; H.R.8267 - Old Drugs, New Cures Act

Client expense: $280,000 · Firm income: Not reported

Government targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

General issues related to health care and pharmaceuticals; drug pricing; patent reform; eye health issues; Medicare issues, including drug price negotiations; FDA issues; FTC issues; H.R.8267 - Old Drugs, New Cures Act

Client expense: $160,000 · Firm income: Not reported

Government targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Medicare and Medicaid payment policies. H.R.8267 - Old Drugs, New Cures Act.

Client expense: Not reported · Firm income: $30,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Medicare and Medicaid payment policies. H.R.8267 - Old Drugs, New Cures Act.

Client expense: Not reported · Firm income: $30,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

General issues related to health care and pharmaceuticals; drug pricing; patent reform; eye health issues; Medicare issues; FDA issues; FTC issues; H.R.8267 - Old Drugs, New Cures Act

Client expense: $160,000 · Firm income: Not reported

Government targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Congressional Personalized Medicine Caucus Precision Medicine Answers for Kids Today Act and Medicaid Early Periodic Screening, Diagnostic and Treatment Benefit 21st Century Cures 2.0 Initiative Response to House Request for Information American Privacy Rights Act provisions related to personalized medicine Oversight of Laboratory Developed Tests H.R. 5539/S. 3131 Optimizing Research Progress Hope And New (ORPHAN) Cures Act H.R. 5547/S.476 Maintaining Investments in New Innovation (MINI) Act H.R. 7174 Ensuring Pathways to Innovative Cures (EPIC) Act H.R. 8267 Old Drugs, New Cures Act H.R. 2407 Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act CMS Implementation of Medicare Drug Price Negotiation Program/ Medicare Drug Price Negotiation Program: Draft Guidance, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2027 and Manufacturer Effectuation of the Maximum Fair Price in 2026 and 2027 Medicare and Medicaid Programs: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; etc (CMS-1809P) Medicare and Medicaid Programs; CY 2025 Payment Policies under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; etc (CMS-1807-P) Agency for Healthcare Research and Qualitys (AHRQs) Review Protocol titled: Blood-based Tests for Multiple Cancer Screening: A Systematic Review Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies [Docket No. FDA-2021-D0789] Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community

Client expense: $44,000 · Firm income: Not reported

Medicare and Medicaid payment policies. H.R.8267 - Old Drugs, New Cures Act.

Client expense: Not reported · Firm income: $30,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE